Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study. by Jassim, Zainab et al.
This is the peer reviewed version of the following article: JASSIM, Z., ELAJEZ, R., KHUDAIR, I., AL ANANY, R., AL-
ADAWI, R.M. 2019. Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic 
patients in Qatar: an observational study. Journal of Pharmaceutical Health Services Research, 10(1), pages 
73-80, which has been published in final form at https://doi.org/10.1111/jphs.12240. This article may be used
for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions
This document was downloaded from 
https://openair.rgu.ac.uk 
JASSIM, Z., ELAJEZ, R., KHUDAIR, I., AL ANANY, R., AL-ADAWI, R.M. 2019. Efficacy and safety of once daily liraglutide 
versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study. Journal of pharmaceutical 
health services research [online], 10(1), pages 73-80. Available from: https://doi.org/10.1111/jphs.12240  
Efficacy and safety of once daily liraglutide versus 
twice daily exenatide in type 2 diabetic patients 
in Qatar: an observational study. 





3 Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 
2 diabetic patients in Qatar: an observational study 4 
5 











































Objective: Compare efficacy and saftey of liraglutide (1.8mg subcutaneous once daily) 
and exenatide (10mcg subcutaneous twice daily) in uncontrolled type 2 diabetes at 26 
and 52 weeks 
Method: A retrospective observation study of uncontrolled type 2 diabetes patients 
who took liraglutide or exenatide in addition to their anti-diabetic medications. This 
study was conducted at Hamad Medical Corporation (HMC), the predominant public 
healthcare organization in Qatar.  The primary outcome was the change in HbA1C after 
26 and 52 weeks. 
Key finding: Two hundred and two patients were included in this study (liraglutide 98, 
exenatide 114). There was no significant HbA1C change observed between two groups at 
either 26 or 52 weeks (p= 0.23 and 0.40, respectively). However, more patients in the 
liraglutide group achieved HbA1C ≤7% at week 26. Liraglutide reduced the mean FBG more 
than exenatide at week 26 and 52. Although both medications were associated with some 
benefits in other studied variables at a certain point (e.g. weight losses, blood pressure), 
neither of them were able to show a significant change from baseline. No patients in either 
group reported drug-related side effects (e.g. nausea and vomiting) or episodes of 
hypoglycemia during the treatment period.  
Conclusions: Exenatide and liraglutide resulted in similar glycemic effects (HbA1C and FPG 
changes) in patients with type 2 diabetes who were sub-optimally controlled with other anti-
diabetic therapy. However, this study supports the effectiveness of both medications for 
weight reduction at both endpoints. A prospective large-scale study is recommended to 
overcome the study limitations. 



























Type 2 diabetes is an increasingly common chronic disease characterized mainly by insulin 
resistance. Many anti hyperglycemic drugs are now available for type 2 diabetes 
management. Most adults with type 2 diabetes need to receive combination therapy of more 
than one class to achieve adequate glycemic control (1). To date, there is insufficient 
evidence to support any specific drug over another. Bayesian network meta-analysis found 
that glucagon like peptide 1 (GLP-1) receptor agonists and insulin were the most efficacious 
agents in lowering Hemoglobin A1C (HbA1C) after metformin failure (2). 
Glucagon like peptide receptor agonists (e.g. exenatide and liraglutide) are injectable drugs 
that are similar to endogenous GLP-1 which usually decreased in patients with type 2 
diabetes (3). It stimulates insulin secretion (in a glucose dependent fashion), suppresses 
glucagon secretion, inhibits gastric motility, and reduces appetite (4, 5). GLP-1 agonists 
lower HbA1C by approximately 1-2 % (6). It also appear to offer advantages over other 
drugs by either keeping weight stable or even reducing weight while achieving good 
glycemic control (7,8). GLP-1 receptor agonists influence weight reduction mainly through a 
centrally mediated mechanism that regulates the appetite, satiety, and food intake (9, 10). 
Another explanation of weight loss associated with GLP-1 receptor agonist treatment can be 
due to its gastrointestinal related adverse effects (e.g. nausea and vomiting). However, this 
explanation is considered weak since patients who did not experience nausea during the 
treatment duration lost weight as well (11). In clinical studies that focused on the cardio-
protective benefits of diabetic medications, GLP-1 agonist (exenatide and liraglutide) showed 
their ability to reduce blood pressure and significantly reduced total cholesterol (TC), low 
density lipoprotein (LDL), and triglyceride (TG) levels compared with baseline (12). The 
most common side effect associated with GLP1-receptor agonists is gastrointestinal 
disturbances, in which 30– 45% of treated patients experiencing at least one episode of 72 
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nausea, vomiting, or diarrhea (13). GLP-1 agonists were rarely found to cause significant 73 
hypoglycemic episodes (14). 74 
There is only one head to head study comparing liraglutide versus exenatide in type 2 75 
diabetes (LEAD-6 study) (15). LEAD-6 results showed that the mean change of HbA1C 76 
values from baseline to week 26 was significantly greater in the group treated with 77 
liraglutide than in that treated with exenatide (p<0.0001) (15). On December 2006, 78 
exenatide (Byetta®) was dispensed for the first time at Hamad Medical Corporation (HMC). 79 
Later on (January 2010), liraglutide (Victoza®) was also available in the HMC pharmacy. It 80 
was unclear if liraglutide (Victoza®) is really more effective than exenatide (Byetta®) and 81 
needed to be added to the formulary as well. Thus the aim of this study was to compare the 82 
effects of exenatide versus  liraglutide on glycemic control (defined as reduction in HbA1C) 83 
over 26, and 52 weeks in patients with type 2 diabetes who could not achieve adequate 84 














Study Design  
A retrospective observation study conducted at Hamad Medical Corporation (HMC), the 
predominant public healthcare organization in Qatar.   
Patients  
Patients with type 2 diabetes who took liraglutide or exenatide in addition to their anti-
diabetic medications during the period of 1st of February 2010 till 30th of January 2012 
were potentially eligible for this study. Pharmacy computer system was used to identify and 
generate list of patients who received liraglutide or exenatide during that period.  Generated 
patient list was screened against inclusion and exclusion criteria. Inclusion criteria were: 1) 
type 2 diabetes patients using either Victoza® (liraglutide 1.8 mg subcutaneous once daily) 
or Byetta® (exenatide 10 mcg subcutaneous twice daily), 2) being compliant with studied 























7.1-11.0%), 4) had a body mass index (BMI) ≤45 kg/m2, 5) had been treated with lifestyle 
modification (diet and exercise) and with at least one other anti-diabetic drug. Patients were 
considered to be compliant if the studied drugs were dispensed at regular basis and patients 
did not run-out of medication at any point during treatment duration. 
Exclusion criteria were:  1) had been treated with herbals or drugs that promote weight loss 
within 3 months before the study baseline or throughout the duration of the study, 2) had 
been taking any herbals or alternative medication for any indications,  3) had done bariatric 
or bypass surgery, 4) were enrolled in or recently discontinued from a study  involving use 
of an investigational drug or device, or any other type judged not to be scientifically or 
medically compatible with this study, 5) and had received long-term (more than 2 weeks) 
systemic glucocorticoid therapy.  
Procedure  
Medical records of eligible patients were retrospectively reviewed from both 1) the patient’s 
paper-based medical file and 2) the patient’s electronic file (i.e. medical database, e-viewer, 
and pharmacy database). Data-collection sheets were completed by the investigators. All 
data were rechecked twice to prevent any missed data.  
Primary and secondary objectives 
Primary: To compare the efficacy between liraglutide (1.8mg subcutaneous once daily) 
versus exenatide (10mcg subcutaneous twice daily) measured by the changing of 
hemoglobin A1C from baseline to 26 weeks, and 52 weeks.  
Secondary:  to compare the effects of liraglutide and exenatide at baseline, 26 weeks, and 
52 weeks in terms of: 120 
 Efficacy: Percentage of patients achieved target HbA1C ≤7%, Fasting plasma121 
glucose (FPG), Body weight and body mass index (BMI), Systolic and diastolic blood122 
pressure, Fasting lipids profile levels (total Cholesterol (TC), low density lipoprotein123 
(LDL), high density lipoprotein (HDL), triglycerides (TG).124 
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 Safety: Gastrointestinal disturbances (nausea, vomiting, or diarrhea), Hypoglycemic126 
episodes (defined as FPG <3.9 mmol/L (70 mg/dL) at any time during the study127 
period and/or dispensing of Glucagon showed on the pharmacy dispensing system,128 

















Statistical analysis  
Descriptive statistics were used to summarize demographic and all other clinical 
characteristics of the patients.  Quantitative variables means between the two independent 
groups were analyzed using an unpaired ‘t’ test and a Mann Whitney U test. Associations 
between two or more qualitative variables were assessed using a chi-square test or Fisher 
exact test as appropriate. Quantitative variables means at different time points (baseline, 
26, and 52 weeks) were compared using repeated measure analysis of variance (ANOVA) 
followed by bonferroni corrections for a multiple comparison test. Relationships between two 
quantitative variables were examined using Pearson’s correlation coefficients. A two-sided P 
value <0.05 was considered to be statistically significant. All statistical analyses were done 
using statistical packages SPSS 19.0 (SPSS Inc. Chicago, IL). 
Ethical consideration  
The study protocol, data-collection sheet, and waiver consent were approved by the HMC 
research and ethics committee.  
Funding  
This study was funded by Hamad research center allied to Hamad Medical Corporation. This 






























Out of 371 identified patients, only 212 patients met the inclusion criteria and were included 
in this study. There were 114 patients in Exenatide group, and 98 in liraglutide group. The 
most common reason for excluding patients was the duration use of exenatide or liraglutide 
was less than 1 year (n= 134). Female gender was dominant in this study, representing 
around 73% in both groups. The mean age for all of the study’s patients was 53 years. A 
round half of the patients in this study were aged between 50–59 years. Patients were 
diagnosed with diabetes for a mean duration of 7.7 years. Generally, there were no 
significant differences in all of the patients’ demographics, co-existing chronic diseases, and 
concurrent medications (including anti-diabetic medications) between the two groups except 
for renal impairment and diabetic neuropathy (Table 1).  
Primary outcome 
The mean HbA1C readings of both exenatide and liraglutide were statistically insignificant 
over the observation periods of 26 and 52 weeks (Table 2). However, comparing the mean 
change of HbA1C values between the two groups, HbA1C was increased from the baseline 
to 26 weeks interval (0.098±0.177) in the exenatide group, while it decreased in the 
liraglutide group (-0.213±0.180). Despite this; the treatment difference between the two 
groups was statistically insignificant (estimated treatment difference (ETD) -0.310; 95% CI -
0.19 to 0.81; p= 0.23). At week 52, the opposite relationship was shown, in which HbA1C 
values increased more in the liraglutide group than in the exenatide group (Figure 1-A). The 
mean change from the baseline to 52 weeks interval was more in the liraglutide group 
(1.399±1.608 ) than in the exenatide group (0.077±0.203) and was statistically insignificant  
(ETD -1.322; 95% CI-4.30 to 1.65; p= 0.40). 
The proportion of participants achieving HbA1C targets of 7% or less was higher in the 
liraglutide than in the exenatide group at 26 weeks (20% vs. 6.4%, respectively) and was 
statistically significant (p= 0.008). Similarly, a higher proportion of liraglutide participants 175 
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achieved HbA1C targets ≤7% at 52 weeks (16.4 % vs. 
insignificant (p= 0.19) (Figure 1-B). 
Secondary outcomes 
Efficacy  181 
182 
1. Fasting Blood Glucose 183 
184 
The mean fasting plasma glucose (FPG) was reduced in both groups at 26 and 52 weeks. 185 
This reduction was statistically significant in the liraglutide group at the three time intervals: 186 
baseline to 26 weeks, baseline to 52 weeks (Table 3). The mean change from the baseline 187 
to 26 weeks interval was greater in the liraglutide group (-1.099±0.518) than in the 188 
exenatide group (-0.122 ±0.432) and was statistically insignificant (p= 0.15). Comparable 189 
results were found in exenatide and liraglutide groups at the 52 weeks interval (-0.616 190 
±0.618; 67, -1.150 ±0.519, p=0.52 respectively). 191 
192 
2. Body Weight 193 
The mean BMI and body weight were reduced at 26 and 52 weeks, in which BMI reduction 194 
was statistically significant in both liraglutide and exenatide groups at both time intervals: 26 195 
weeks (p=0.023, p=0.015, respectively), and 52 weeks (p=0.002, p=0.002, respectively). 196 
On the other hand, body weight reduction was statistically significant at both 26 and 52 197 
weeks only in exenatide group, while the liraglutide group was statistically significant only at 198 
52 weeks. 199 
200 
3. Blood pressure 201 
202 
At week 26, the systolic blood pressure (SBP) increased in the exenatide-treated group, 203 
while it slightly decreased in the liraglutide group. On the other hand, the diastolic blood 204 
pressure (DBP) decreased in the exenatide-treated group, while it increased in the liraglutide 205 
group (Figure 2-A,B). At 52 weeks, both the systolic and diastolic blood pressure reduced in 206 
9 
both treatment groups (compared with week 26) and the reduction was more in the 207 
liraglutide group than in the exenatide group (Figure 2-A, B). Comparing the change of 208 
blood pressure between the two groups retrieved no statistical difference at any time point. 209 
210 


















Total cholesterol and LDL were reduced in the liraglutide group at both time points (26 and 
52 weeks) but it was statistically significant only at the baseline–52 week’s interval. Other 
parameters (HDL, Triglycerides) were statistically insignificant over the observation periods. 
All lipid profile parameters (TC, LDL, HDL, and TG) were statistically insignificantly changed 
in exenatide group at both time points (Figure 2-C, D). Comparing two groups together, 
none of the profile parameters showed any statistically significant difference. 
Safety 
None of the patients in either groups reported any GI side effects (nausea, vomiting, and 
diarrhea) or hypoglycemic episodes. For other safety parameters regarding kidney and liver 
functions, none of the changes in these parameters were significant at any time points 
except for creatinine in the liraglutide group at 52 weeks (p=0.001) (Table 4).  
Overall, the exenatide group had a better safety profile than the liraglutide group in all 
kidney and liver function parameters in both time points, except for AST at 26 weeks.  For 
example, at week 52, the mean reduction of ALT from baseline was (-1.483±1.278) in the 
exenatide group, which is better than the ALT elevation occurred in the liraglutide group 









In this study, the mean age of the patients was 53 years, 73% of them were female, and 
more than 90% were Middle Easterners. These demographic findings are in line with the 




























UKPDS found that a reduction of 1% in HbA1C was associated with a 37% decrease in 
micro-vascular complications and a 21% decrease in mortality associated with diabetes (17). 
Thus, selection of HbA1C reduction as a primary outcome is clinically relevant and well 
justified. In the current study, results showed that in type 2 diabetic patients with 
inadequate glycemic control on other anti-diabetic medications, neither the addition of 1.8 
mg liraglutide nor 10 mcg exenatide provided significant glycemic control after 26 or 52 
weeks of treatment compared to baseline. The beneficial effects of liraglutide over exenatide 
seen at week 26 were aligned with those reported in the only liraglutide versus exenatide 
head-to-head study (LEAD-6) (15). The LEAD-6 results showed that the mean change of 
HbA1C values from baseline to week 26 was significantly greater in the group treated with 
liraglutide than in that treated with exenatide (p<0.0001).  
Unlike the previous studies of either liraglutide or exenatide when each drug was studied 
separately, in the present study, liraglutide 1.8 mg once daily reduced HbA1C by a mean of 
0.213% after 26 weeks compared with a reduction of 1% in the LEAD-2 study (18), 1.1% in 
the LEAD-1 study (19), 1.3% in the LEAD-5 study (20) and 1.5% in both the LEAD-4 and 
DURATION-6 studies (21, 22).  
Additionally, the current results and the previous studies’ results, exenatide 10  mcg twice 
daily slightly increased HbA1C values by a mean of 0.098% and 0.077% at 26 weeks and 52 
weeks, respectively. This increase was not consistent with other trials in which HbA1C was 
reduced by approximately 1% (12, 23-26). The reasons for this unexpected difference in 
HbA1C changes noted in this study for both liraglutide and exenatide are unknown; 
however, previous pharmacological exposure, study population, or medication compliance 
might have contributed to the differences.  263 
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Secondary Outcomes 264 
265 
 Fasting Plasma Glucose 266 
267 
Fasting plasma glucose (FPG) is an important measure of glycemic control, where fasting 268 
hyperglycemia contributes to the chronic complications of diabetes (11). In this study, FPG 269 
was decreased in both groups at 26 and 52 weeks, but the decrease achieved statistical 270 
significance only in the liraglutide group. Although liraglutide also showed greater FPG 271 
reduction over exenatide in the LEAD-6 study, the mean reduction at 26 weeks reported in 272 
the LEAD-6 study (3.2 mmol/L for liraglutide, and 2.9 mmol/L for exenatide) was much 273 
higher than what was shown in the current study (1.1 mmol/L for liraglutide, and 0.12 274 
mmol/L for exenatide) (16).  275 
In the current study, the mean reduction in FPG in the exenatide group was out of the 276 
reduction range (1-2 mmol/L) reported in other trials at both 26 and 52 weeks (11, 12, 25, 277 
27,28). Unpredictably, liraglutide patients continued to have FPG reduction at week 52 278 
despite the elevation of their HbA1C at that endpoint. Therefore, reduction in FPG is not 279 
always translated into a reduction in HbA1C.  280 
 Body Weight, blood pressure and lipid profile: 281 
282 
In line with the beneficial effects of exenatide and liraglutide in weight reduction approved 283 
in previous trials (7, 8), the current study showed that patients’ weights were significantly 284 
reduced at 26 and 52 weeks in both groups compared to their baseline weight, except for 285 
the liraglutide group at 26 weeks. However, there was no treatment differences between the 286 
two groups at both time points similar to the LEAD-6 study (p=0.2235) (16). 287 
Noteworthy that both exenatide and liraglutide showed reductions in blood pressure (SBP 288 
and DBP) occurred in the two groups at both 26 and 52 weeks. Although the SBP reduction 289 
reported in the LEAD-6 trial was much greater in both groups than reported in this study 290 
(16). Moreover, they demonstrated beneficial effects on lipids parameters (e.g. TC, TG, and 291 
12 
LDL); liraglutide provided better non-significant lipid improvement versus exenatide with 292 
exception of HDL which improved more in exenatide patients. In spite of both groups 293 
experiencing an unpredicted elevation of TG at week 52, liraglutide produced a more 294 
substantial TG elevation than exenatide did. However, the mean change in lipid levels in this 295 
study was lower than that reported in previous trials (12, 25). 296 
 Hypoglycemic Episodes 297 
298 
In previous trials, GLP-1 agonists were not associated with a significant increase of 299 
hypoglycemic episodes unless combined with other drugs that elicited hypoglycemia (27). 300 
There is no event of hypoglycemia in this study neither as minor no major episodes. In the 301 
LEAD-6 study, no major hypoglycemia occurred with liraglutide while only two episodes 302 
happened with exenatide patients (16).  303 
 Gastrointestinal Disturbances304 
305 
The proportion of patients experiencing nausea in LEAD-6 was initially similar in the two 306 
groups; however, nausea was resolved more quickly in patients treated with liraglutide than 307 
in those treated with exenatide (16). In the current study, unfortunately, none of the 308 
patients in both groups reported any GI side effects as nothing was documented in their 309 
files.   310 
 Strengths and limitations 311 
312 
This study had several strengths that are worth mentioning. The notable strengths of this 313 
study that; it was being the first of its kind in Qatar, and indeed the entire Arabian Gulf 314 
region, to present a head-to-head comparison of exenatide (10 mcg twice daily) versus 315 
liraglutide (1.8 mg once daily) in type 2 diabetic patients other than the LEAD-6 study. 316 
Moreover, a longer duration when compared to the LEAD-6 study, which gives deep insight 317 
about the long-term effect of liraglutide and exenatide. In addition to, There were no 318 
statistically significant differences between the two groups regarding other anti-diabetic 319 
13 
medications that patients were concurrently taking with the studied drug, providing the 320 
study with the advantage of eliminating any possible confounder factors that could affect 321 
the reliability of the study results’ and ensuring that the reported results truly represented 322 




















In conclusion and on the basis of the results of this study, it seemed that there was no 
statistically significant efficacy difference between liraglutide and exenatide in terms of 
reduction in HbA1C and FPG. However, this study supports the effectiveness of both 
medications for weight reduction where both medications caused weight loss (and 
consequently BMI reduction) at both endpoints (26 and 52 weeks). Although these 
medications were associated with some benefits in other studied variables at a certain point, 
neither of them was able to show a significant change from baseline. No patients in either 
group reported drug-related side effects (e.g. nausea and vomiting) or episodes of 
hypoglycemia during the treatment period.  
Overall, the current study highlights the importance of further studies to be done to 
compare the efficacy and safety of liraglutide and exenatide in type 2 diabetic patients. A 
prospective large-scale study is recommended to overcome the previously mentioned 
limitations. Until that, this study hopefully will be used to better inform healthcare providers, 
and this will eventually translate into an increase in the health benefits and awareness for 
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